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Introduction: The prevention of schizophrenia and other psychotic disorders has led 
researchers to focus on early identification of individuals at clinical high risk (CHR) for 
psychosis and to treat the at-risk symptoms in the pre-psychotic period. Although at-risk 
symptoms such as attenuated hallucinations or delusions are common in adolescents 
and associated with a marked reduction in global functioning, the evidence base of 
effective interventions for adolescents at CHR state and even first-episode psychosis 
is limited. Thus, the present protocol describes a study design that combines therapy 
modules for CHR adolescents with a smartphone application supporting the young 
individuals between the therapy sessions. The treatment approach “Robin” is based 
on existing therapy strategies for adolescents with first episode of psychosis and the 
available recommendations for adults with at-risk symptoms.
Methods: The evaluation aims firstly to compare the efficacy of Robin in 30 CHR 
adolescents aged 14–18 to an active control group (treatment as usual) from a previous 
study. Primary outcome measures will be at-risk symptomatology, comorbid diagnosis, 
functioning, self-efficacy, and quality of life. For the prospective intervention condition (16 
weekly individual sessions  +  a minimum 4 family sessions), help-seeking adolescents 
with CHR for psychosis, aged 14–18, will be recruited over 3 years. At-risk and comorbid 
symptoms, functioning, self-efficacy, and quality of life are monitored at six time points 
(baseline, during the treatment period; immediately after intervention; and 6, 12, and 
24 months later) and compared with the respective measures of the active control group.
Discussion: To the best of our knowledge, this is the first controlled trial to test the efficacy 
of a specific early psychosis treatment in combination with a smartphone application for 
adolescents at CHR for developing psychosis. The results of the study are expected 
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to add information that may substantially decrease the burden of CHR adolescents 
and increase their resilience. It may offer age-adapted and targeted strategies to guide 
clinicians in the treatment of these vulnerable individuals. Furthermore, research in the 
field of early intervention will be enriched by our findings.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT03829527.
Keywords: psychosis, eMental health, psychological intervention, youth mental health, clinical high risk of 
psychosis, early intervention
INTRODUCTION
Psychotic disorders are severe mental illnesses that typically 
emerge in late adolescence or early adulthood (1). The disorders 
lead to considerable social and economic deficits, as well as 
burden for the individual and family (2). Prior to the onset of the 
first psychotic episode, the majority of the individuals experience 
attenuated psychotic symptoms, known as at-risk symptoms (3).
Two different sets of clinical high risk (CHR) criteria have 
been developed for the purpose of early identification of 
individuals at CHR: 1) the basic symptom criteria focusing 
on subtle, subjectively experienced changes in cognition and 
perception and 2) the ultra-high-risk criteria, such as attenuated 
positive symptoms indicating the imminent manifestation of 
psychosis (4). In the present article, we use the term CHR state, 
which includes both of these current risk concepts.
There is an ongoing discussion as to whether or not to 
treat at-risk symptoms (5–7). The rates of CHR individuals 
transitioning to psychotic disorders have declined over the years 
of early detection research (8), and the specificity of at-risk 
symptoms is questioned (5, 9). At-risk symptoms are common 
in the general population, particularly during adolescence; it is a 
clinical challenge as to how to differentiate between young people 
who are at risk and those who are not (10, 11). Nevertheless, 
leading experts in the field of early intervention in psychosis have 
claimed that treatment of at-risk symptoms in the help-seeking 
population is justified independently of the risk of conversion to 
psychosis [for example, Refs. (12–15)].
CHR individuals and their caregivers report high levels of 
distress due to these symptoms (16). The CHR state is associated 
with suicidality, impairments to global functioning, and a decline 
in quality of life (17–23). CHR individuals report poorer social 
relationships and higher rates of loneliness than do healthy peers 
(24). Furthermore, CHR individuals seem to have poor coping 
skills, low levels of self-efficacy, and negative metacognitive belief 
similar to that seen in patients with depression or with a frank 
psychosis (25–27). Recent studies have shown a high prevalence 
of psychiatric comorbidities in CHR populations for psychosis 
(28, 29), especially in younger CHR individuals (20). Moreover, 
the CHR state is associated with long-term implications, 
independent of conversion to psychosis. A recent study showed 
that about half of non-transitioned CHR individuals remained 
functionally impaired and presented with at least one comorbid 
disorder at a 6-year follow-up (30). On the other hand, CHR 
individuals who convert to psychosis have shown poorer clinical 
outcomes than do first episode psychosis patients without a 
history of at-risk symptoms (31). Consequently, current data 
clearly favor targeting and treating at-risk symptoms in help-
seeking individuals.
Although at-risk symptoms are common in adolescents 
and associated with a marked reduction in functioning in this 
age group (23), the evidence base required to guide effective 
interventions for CHR adolescents and even ﬁrst-episode 
psychosis is limited (15, 32–35). Most intervention studies in 
the CHR population have included adult patients, with only 
a few including younger patients (36–40). A majority of them 
used the same treatment approaches for adults and adolescents. 
Consequently, there is a lack of investigation targeting age-
appropriate treatment strategies in this vulnerable age group. 
The transition from childhood to adulthood is a very complex 
developmental stage, and age-adapted intervention strategies are 
required. The CHR state can disrupt social and psychological 
development, such as the achievement of educational goals or 
the construction of peer relationships. Therefore, minor CHR 
individuals need treatment strategies that address the complex 
symptomatology, the associated burden, and their reduced 
functioning. Furthermore, when focusing on engagement in 
therapy during first psychotic episodes, the data demonstrated 
that age-appropriate treatment approaches drawing from youth 
specific interests are needed to address and involve the younger 
patients (32, 41).
To fill this gap, the experts from the specialized outpatient 
care unit for early intervention in psychosis at the Department of 
Child and Adolescent Psychiatry and Psychotherapy, Psychiatric 
University Hospital of the University of Zurich (CAPS), developed 
the specialized treatment approach “Robin” for CHR adolescents. 
The treatment program Robin is an integrated psychotherapeutic 
approach. Robin comprises individual therapy, family sessions, 
and a smartphone application for supporting patients between 
sessions. The therapy modules are based on treatment strategies 
in CHR adults (6, 14, 42–44) and recommendations for 
adolescents with first episodes of psychosis (33, 45, 46). It follows 
the guidance on early intervention in CHR states of psychosis of 
the European Psychiatric Association (EPA) (15).
The treatment modules are also based on existing concepts 
of cognitive behavioral therapy (CBT). CBT is currently the 
most widely approved psychological intervention in early 
intervention of psychosis and recommended by EPA guidance 
(15). Previous studies showed that CBT may prevent or at least 
postpone a first psychotic episode in CHR individuals (47); 
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however, these promising findings need replication, and studies 
applying CBT in adolescents are rare. Cognitive remediation 
is used as a supplement treatment and focuses on improving 
cognitive and social skills. Additionally, the treatment modules 
comprise aspects of systemic therapy, which have been found 
to be efficacious in the treatment of psychosis in adult patients 
(48). Assuming that family environment plays a more relevant 
role in adolescents than in adults, there is a strong rationale for 
the possible benefits of systemic intervention in adolescents with 
CHR state. The initial studies of systemic treatment approaches 
in adolescents with psychosis (32) and CHR adolescents are 
promising (36, 39).
In addition to the above, the intervention also includes the 
smartphone application “Robin Z.” Smartphones have become 
everyday devices, and most people use them in their daily routine. 
Previous analyses showed that for young people, in particular 
“digital natives,” it may be helpful to develop technology-based 
treatment approaches as a way of connecting with them about 
mental health issues (49–51). There is increasing interest in using 
mobile technologies such as smartphone applications in mental 
health care (52–54). Primarily, mobile technologies were utilized 
to collect research data. These technologies allow for real-time 
assessment. This provides more accurate data about real-world 
contexts in which experiences are made or behaviors occur (55, 
56). So risk and protective factors in the psychosocial environment 
and their impact on mental health can be more easily identified. 
Further, studies with smartphone assessments showed higher 
engagement in completing all examinations and lower dropout 
rates than did studies with paper-and-pencil assessments (57, 
58). Recently, research projects have examined feasibility and 
validity of mobile technologies in supporting therapy (53, 
59). Smartphone interventions have many advantages like 
accessibility, portability, 24-h support, or real-time intervention. 
Using smartphones in everyday situations (i.e., on the bus, at 
school, and on the street) is routine, and so interventions via 
smartphone are not likely to be stigmatizing (49). The problem 
of recall bias in retrospective reports can be reduced or avoided. 
This helps the psychotherapist to give more tailored feedback to 
support and reinforce changes in the patients’ behavior according 
to their psychological health. Furthermore, self-monitoring also 
provides advantages for the patients themselves. The repeated 
measurement of their symptoms and mood can reveal insights 
into their psychological processes (60). Reid and colleagues (61) 
found an increased self-awareness regarding their symptoms and 
mood after using a symptom-monitoring smartphone application 
in a group of younger psychiatric patients. There is also evidence 
that medication adherence can be improved through smartphone 
intervention (62, 63).
In the treatment of psychotic disorders, the first research 
results from the use of smartphone applications are promising 
(62, 64–68); however, there is little known about mobile 
technologies addressing at-risk symptoms (50). Despite current 
analysis demonstrating young people would be interested in 
using mobile technologies, there is a lack of investigations with 
this population (49, 51). The available studies have shown a high 
acceptance and subjective satisfaction with mobile interventions 
in young people with psychiatric problems (57, 61, 69).
There is great heterogeneity across symptomology and 
functioning in the CHR population (30, 70). As a consequence, 
individualized adaptive treatment approaches are required. 
While some individuals will respond to an intervention, others 
will not. Robin is an individually tailored approach, and the 
treatment is personalized to the individuals’ special needs 
depending on their stage of illness, presence of comorbidities, or 
functional impairment.
The current clinical trial “Evaluation of the Treatment 
program Robin” (ETRo) has two main study goals:
(1) to investigate the feasibility and impact of the combined 
treatment program: the structured therapy and the 
smartphone application; and
(2) to investigate the efficacy of this specific intervention versus 
treatment as usual (TAU).
Hypotheses of the study:
Hypothesis 1: Robin is feasible and accepted in this young 
population of CHR individuals. The adolescents will 
show high treatment engagement.
Hypothesis 2: Robin improves the quality of life and 
self-efficacy at 6-, 12-, and 24‐month follow-up in 
individuals with CHR compared with individuals with 
CHR who received TAU.
Hypothesis 3: Robin enhances the rate of adolescents with 
clinical and psychosocial functional remission at 6-, 
12-, and 24‐month follow-up than does TAU.
METHODS AND STUDY DESIGN
The ETRo Trial is a prospective, single-center, follow-up study 
comparing a specific treatment program for adolescents with 
at-risk symptoms with a sample from a previous study having 
received TAU.
Participants
Participant recruitment will run between September 2017 and 
continue until September 2020 in the early recognition center 
for psychosis of the Department of Child and Adolescent 
Psychiatry and Psychotherapy, Psychiatric University Hospital 
of the University of Zurich (CAPS). The ETRo trial is a 
naturalistic treatment study. All participants will be help-seeking 
adolescents (aged 14–18) with at-risk symptoms assessed at the 
early recognition center. The purpose of the study, the study 
process, risks, benefits, and alternatives will be explained to all 
participants and their caregivers according to ethical principles. 
All participants will be asked to give a written informed consent 
in accordance with the national law. For inclusion, participants 
must meet at least one of the following at-risk criteria: 1) at least 
two self-experienced and self-reported cognitive basic symptoms 
as assessed by the Schizophrenia Proneness Interview Child and 
Youth Version (SPI-CY) (71) and/or 2) at least one attenuated 
psychotic symptom for psychosis assessed by the Structured 
Interview for Prodromal Syndromes (SIPS) (72).
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Exclusion criteria for study participation include a diagnosis 
of a psychotic disorder, current substance or alcohol dependence, 
aged below 14, insufficient German or English language ability, 
or low intellectual abilities with IQ < 75.
Study Design
Within this prospective evaluation data for at-risk symptoms 
and comorbid symptoms, global functioning, self-efficacy, and 
quality of life will be collected at six time points (baseline, during 
the treatment period; immediately after intervention; and 6, 12, 
and 24  months later). The treatment period will be 16 weekly, 
individual sessions combined with at least four family sessions 
starting after the baseline clinical assessment (Figure 1).
Study Intervention
The integrated psychotherapeutic treatment approach Robin 
combines standardized treatment modules with a smartphone 
application. The treatment is targeted at at-risk symptoms as 
well as comorbid disorders. Improving quality of life and daily 
functioning is also a primary target in therapy and outcome 
measures. An important part of the program is the work on the 
individuals’ self-esteem and their experience of self-efficacy. 
The program is solution and resource oriented in reframing 
one’s symptoms. A variety of questioning techniques are used to 
enrich the individuals’ perspectives, to identify problems, and to 
create more possibilities in dealing with daily difficulties. Weekly 
homework tasks are usually given to transfer the insights and 
experiences from the therapy in the individuals’ daily life.
The first session is a family session directly after the 
clinical baseline assessment. In this session, there is a detailed 
psychoeducation to develop a concept of the CHR state with 
the adolescent and their caregivers. The therapeutic goals will 
be declared. The therapeutic modules provide information 
and individual approaches to target specific complaints of the 
adolescent within the following 15 sessions. The individuals 
are asked to make a daily record of their symptoms, mood, 
sleeping patterns, and alcohol and drug use over the entire 
treatment period. The records are discussed every week in the 
first part of the therapy session.
The psychotherapists consist of two female graduated 
psychologists, NT-W and SM, trained in research early 
recognition programs and experienced in treatment of clinical 
outpatients. MF, medical doctor, head of the early recognition 
FIGURE 1 | Flow chart of the assessments from baseline to 24 months of follow-up.
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service for adolescents, and the respective psychologist will 
conduct the family sessions together.
In accordance with the EPA guidance (15), low-dose second-
generation antipsychotics are used when at-risk symptoms are 
severe and progressive with only minimal or clearly declining 
insight. The medication is monitored and supervised by M. F.
App Robin Z
The app Robin Z (Figure 2) was developed to enrich the treatment 
sessions. A modular version of the app was developed and 
modified after the first pilot investigations with patients (N = 7, 
aged 14–18) and clinicians from the CAPS (N = 10). All clinicians 
within the pilot study reported that they would like to use the 
app Robin Z to enrich their therapeutic approaches. All patients 
in the pilot project used the app in their daily lives. Modules 
containing information about symptoms and coping strategies 
were used most frequently by patients. The findings were used 
to improve and adapt the application. In September 2017, the 
development of Robin Z was finalized and published on iTunes 
and Google Play. The technical aspects of Robin Z are regularly 
maintained without changes to the content.
The app is developed as an adjunct to the therapy and not a 
replacement for appropriate medical treatment and management. 
It is not at treatment itself, and it is not seen as a medical product 
according to the Swiss Medical Devices Ordinance Act. The 
authors recommend using the app in combination with a 
psychological treatment. Furthermore, it may be a used after 
completion of the study and/or therapy.
The app works offline and is not connected to the internet. 
Data collected by the app are stored in a private directory. These 
data are protected by the operating system and are inaccessible to 
other software on the device. The app does not transfer or store 
any data on the internet, and no data are stored outside of its 
private directory. In addition, the app is also password protected.
The app contains the following features:
Symptom management: Users will receive information about 
their symptoms and suggestions for managing them via the app. 
In therapy, these coping strategies are discussed with the patient 
and, if necessary, explained by the clinician. The adolescents can 
also define their own coping strategies and note helpful thoughts 
under the function “Memo.” The adolescents will be asked about 
their symptoms and their mood several times a day. They agree 
together with their therapists how many prompts they will receive 
each day. The symptom records are saved under a “Logbook.”
Medication: The individuals can record their medication, 
and they can set up a reminder. Medication adherence can be 
monitored through the Logbook.
Crisis intervention: In collaboration with their therapists, 
adolescents can set up a crisis intervention plan including 
emergency contacts. They can call the emergency contact 
directly via the app.
Weekly goals: The individuals can set their own goals. This 
means small, attainable goals so that they experience success. 
Furthermore, they are supported when dealing with their daily 
challenges. The goals are decided in the therapy session.
Library: The “Library” offers positive reinforcement for dealing 
with daily life. It consists of a list of strengths and positive experiences. 
The lists of strengths and positive experiences are discussed and 
extended on every week in therapy. There are suggestions for 
positive activities that the adolescents can engage in daily. The 
individuals are encouraged to do at least one positive activity per 
day. The suggestions are split into the following categories:
• Reward
• Creative activities
• Movement
• Social interaction
• Cognitive training
• Wellness
• Relaxation exercises
Standard Care
The control condition is composed of a control group from a 
former early recognition study in Zurich (ZInEP) [e.g., Ref. 
(73)]. The control group consists of 62 adolescents meeting 
CHR criteria (25 female, age range 13–18 years, mean age 15.06) 
who historically signed a declaration of consent regarding the 
use of their data. The sample was accrued from April 2010 to 
July 2012. The individuals of this subsample of the ZInEP had 
been treated with non-standardized psychological intervention 
(TAU) also at the CAPS. Within the ZInEP study, the comparable 
primary and secondary outcomes (at-risk symptoms, comorbid 
symptoms, global functioning, self-efficacy, and quality of 
life) have been evaluated at the same time points (at baseline 
and 6, 12, 24, and 36  months later). Since we expect a high 
interindividual variability of symptom fluctuation, reduction, 
or progression during the phase of intervention, we plan to 
reduce further putative impact of sex and age and to match 
individuals from the intervention group to ZInEP individuals 
accordingly. Consequently, 30 individuals from the ZInEP 
sample will be included in the statistical analysis.
Primary Outcome
Primary outcome measures are transition to psychotic disorders, 
changes in at-risk as well as comorbid symptomatology, global 
functioning, life quality, and self-efficacy. All these measures will 
be compared with those of the control group.
Secondary Outcome
Secondary outcome measures are the feasibility, user-friendliness, 
and acceptance of the treatment program Robin and the 
smartphone application Robin Z. Therefore, discontinuation of 
the therapy and subjective satisfaction with the therapy will be 
assessed. Furthermore, data about hospitalization, suicidality, 
and medication adherence will be collected and analyzed in 
comparison with those of the control group.
Assessment
At baseline, demographic variables, past psychiatric illness, and 
treatment information are obtained from the participants and 
their caregivers. Before participating in the study, all patients will 
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undergo a clinical assessment and diagnostic process according 
to International Classification of Diseases, Tenth Revision, criteria. 
Adolescents will be asked to complete a questionnaire about 
their personality traits PSSI (74) and to perform the Wechsler 
Intelligence Scale for Children (75) or Wechsler Adult Intelligence 
Scale for individuals aged > 16 years 11 months (76) to evaluate 
their cognitive profile.
In accordance with EPA guidance on the early detection of CHR 
states of psychoses, the CHR status is assessed with the Schizophrenia 
Proneness Interview Child and Youth Version (71) and the 
Structured Interview for Prodromal Syndromes (72). All investigators 
are either psychologists or psychiatrists. They are trained to a “gold 
standard,” and reliability will be measured for the duration of the 
trial. Comorbid mental disorders will be screened for with the 
Mini-International Neuropsychiatric Interview for Children and 
Adolescents based on Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition (77). The severity of depression will be 
measured using theHamilton Depression Scale (78).
Information about functioning will be measured with the 
Global Assessment of Functioning Scale (GAF) (79), Social and 
Occupational Functioning Assessment (SOFA) Scale (80), and 
Global Functioning: Social Scale (GF: Social) (81). Data about 
quality of life, personality traits, and self-efficacy will be collected 
using the Manchester Short Assessment of Quality of Life 
(MANSA) (82) and the General Self-Efficacy Scale (SWE) (83).
Treatment satisfaction will be evaluated with the treatment 
evaluation questionnaire for adolescent patients FFB-J (84). 
A feedback form created specifically for the app will gather 
information regarding acceptance and contentment with the 
smartphone application Robin Z (Table 1).
Statistical Analysis
Statistical analysis will be reported in accordance with the 
Consolidated Standards of Reporting Trials statement.
Clinical Analyses
Differences in the primary and secondary outcomes between 
the two study groups at all time points will be examined with 
repeated measures analysis of variance and standardized effect 
sizes (Cohen’s d) will be reported. Their respective confidence 
intervals will be calculated for comparison. Response and 
remission rates will be compared across groups with contingency 
tables and differences tested with χ2. All unidirectional 
hypotheses will be tested one sided; bidirectional hypotheses will 
be tested two sided. Alpha is set to p < 0.05. All analyses will be 
conducted within SPSS.
A linear mixed model approach will be used to assess 
differences in the primary and secondary outcomes between 
the two study groups. Logistic regression will be used to assess 
response and remission rates across the groups. Medication, 
education, and intelligence will be taken into account as 
confounding factors by including them in mixed model and 
logistic regression model, respectively. All unidirectional 
hypotheses will be tested one sided; bidirectional hypotheses 
will be tested two sided. Significance level α is set to 0.05.
FIGURE 2 | Example screenshots of the app Robin Z.
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Sample Size
The sample size calculation is based on testing differences between 
the TAU group and the intervention group. It has been assumed 
that the intervention group could achieve at least 10% additional 
improvement than the TAU group for the main instruments at 
the 6-month follow-up assessment (Table 2). Standard deviations 
for the different instruments have been estimated with data from 
adolescent participants of a previous early recognition study (73). 
Sample size calculation was assessed using SAS PROC Power, 
Version 9.4.
To the best of our knowledge, there is no comparable study 
reporting effect sizes of the improvement of clinical outcome 
variables such as overall symptom dimensions and functioning in 
CHR adolescents. Considering the respective outcome measures, 
the sample size ranges from 16 to 27 (Table 2). In a conservative 
approach, we chose to include 30 individuals per group.
Data Monitoring and Management
Study data will be entered onto a study specific database 
(Research Electronic Data Capture REDCap) following a 
standard operating procedure. All data will be collected on paper 
case report forms (CRFs) that are anonymized and stored at the 
CAPS. Data will be entered by researchers electronically into 
the REDCap database. A random subset of data will be checked 
for quality control by independently checking the paper CRFs, 
and electronically entered data and any errors will be corrected. 
Only the leading investigators, trial statistician, and researchers 
will have access to the final dataset.
TABLE 2 | Numbers needed to detect a significant difference between TAU and the intervention group for the different psychological instruments.
Instrument Assumed additional improvement in 
comparison with TAU
(∑ Total points per scale)
Maximum
(∑ Total points)
N per group
SIPS −15 114 17
SPI-CY −9 84 16
SWE +4 40 27
GAF +10 100 24
GAF, Global Assessment of Functioning Scale; SIPS, Structured Interview for Prodromal Syndromes; SPI-CY, Schizophrenia Proneness Interview Child and Youth Version; SWE, 
General Self-Efficacy Scale; TAU, treatment as usual.
TABLE 1 | Description of assessments from baseline to endpoint of study.
Baseline Intervention
(16 session)
Follow-up
Time point (months) 0 2 4 6 12 24
Socio‐demographic characteristics x x x X x x
Clinical diagnosis according to ICD-10
Re-evaluation of all diagnoses
x
x x X x x
Medication x x x X x x
Intellectual ability:
WISC/WAIS x
Personality traits:
PSSI x x
Clinical High Risk State:
SPI-CY
SIPS
x
x
x x
x
x
x
x
x
x
x
Comorbidities:
MINI KID x x x x x x
Depression:
HAMD x x x x x x
Functioning:
GAF,
GF: Social
SOFAS
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
Quality of Life:
MANSA x x x x x x
Self-efficacy:
SWE x x x x x x
Satisfaction with treatment:
FFE
Feedback form regarding app Robin
x
x
GAF, Global Assessment of Functioning Scale; GF, Social, Global Functioning: Social Scale; HAMD, Hamilton Depression Rating Scale; ICD-10, International Classification of 
Diseases, Tenth Revision; MANSA, Manchester Short Assessment of Quality of Life; SIPS, Structured Interview for Prodromal Syndromes; SOFAS, Social and Occupational 
Functioning Assessment Scale; SWE, General Self-Efficacy Scale; WAIS, Wechsler Adult Intelligence Scale; WISC, Wechsler Intelligence Scale for Children.
Treatment Approach for Adolescents at CHRTraber-Walker et al.
8 June 2019 | Volume 10 | Article 384Frontiers in Psychiatry | www.frontiersin.org
Serious adverse events are regularly monitored and documented 
by the research team and reported immediately to the chief 
investigator and/or a senior clinical member of the team.
Ethical Issues
This study is being conducted in accordance with globally 
accepted standards of good clinical practice, in agreement with 
the Declaration of Helsinki and with national regulations of the 
Swiss Ethics Committees on research involving humans. The local 
ethics committee in Zurich has approved the study procedure, 
study information, and informed consent forms in Mai 2017 
before the inclusion of a first patient in the trial. The study has 
been registered at the international trial register ClinicalTrials.
gov (ClinicalTrials.gov identifier NCT03829527) and the national 
trial register kofam (kofam.ch identifier SNCTP000003148).
Every participant can drop out of the study at any time. All 
dropouts will be documented in the CRFs. The study investigators 
ensure that all mental health professionals involved in the study 
are qualified and informed about the protocol, interventions, and 
trial-related duties.
DISCUSSION
Despite evidence suggesting that young individuals with at-risk 
symptoms may profit best from specialized treatment approaches 
(85), little is known about age-appropriate treatment strategies in 
this vulnerable age group (15). The treatment program Robin has 
been developed to fill this gap.
Our treatment approach Robin is an integrated approach 
based not only on CBT but also on systemic therapy. The 
treatment is both solution and resource focused. Furthermore, 
Robin is an individualized treatment approach in line with the 
individual needs of the particular patients, which should lead 
to a high acceptance. Furthermore, age-appropriated treatment 
material, including a smartphone app and the involvement of 
the family, may result in higher engagement in therapy (32, 41, 
49). The smartphone application Robin Z has been developed 
to enrich the treatment and to increase treatment satisfaction 
through providing support between sessions. Previous studies 
have already demonstrated that mobile-based interventions are 
feasible and accepted by psychotic patients (49, 58, 59, 66); thus, 
we expect the same for CHR individuals.
In accordance with EPA guidance in early intervention in 
CHR states of psychoses (15), a primary aim of this treatment 
approach is to improve the daily functioning. Thus, the study 
group decided to primarily focus on quality of life, self-
efficacy, and functioning. These areas have been shown to be 
most impacted in adolescents and often prompt them to seek 
help (18, 30, 44, 86, 87). In contrast, at-risk symptoms are not 
necessarily the cause of the highest psychological strain and 
burden for the patient. Furthermore, we expect a remission 
or at least a significant decline of the at-risk symptoms in 
most patients after the treatment period. Prior evidence has 
demonstrated that at-risk symptoms, especially in adolescents, 
show high levels of fluctuation (70, 88). How much this 
fluctuation symptoms or remission rates are associated with a 
specific intervention is currently unknown. Our first analysis 
of symptomatology in the control group also showed a high 
reduction of at-risk symptoms during follow-up compared 
with the baseline.
The integrated and age-adapted treatment approach as well 
as the focus on outcomes other than the putative progression 
of symptomatology and onset of psychosis also seems to be 
supported by a recent network meta-analysis. Davies et al. 
(89) compared efficacy of different preventive interventions 
in CHR individuals considering conversion rates in psychosis 
and acceptability of treatment intervention. The findings 
demonstrated a lack of evidence to favor a specific intervention 
to prevent onset of psychosis, and there were no significant 
differences in acceptability between the treatment approaches. In 
the context of non-superiority of any intervention, the authors 
questioned CBT as the most widely adopted intervention in the 
early intervention of psychosis.
Using a control group of our previous early recognition 
study ZInEP and a non‐randomized design could be possible 
sources of bias. However, data of the control group participants 
of ZInEP were reassessed at the same time points (6, 12, and 
24  months), and identical measures were used. The TAU was 
carried out in the same outpatient service under the supervision 
of M. F. There were no major changes in the Swiss health system 
between 2010 and 2018 that could have had an influence on the 
frequency or intensity of therapeutic sessions. The outpatient 
mental healthcare system in Zurich has remained widely 
unchanged since then. Another limitation of the control group 
may be the naturalistic setting. As their treatment was not 
standardized, many treatment variables, such as the treatment 
approach or the therapists themselves, cannot be controlled 
for. However, even though a moderate sample size may limit 
statistical controlling, important confounders such as effect of 
medication, hospitalization, and treatment frequency may be 
identified in both groups and controlled for. Our control group 
is an extensively and carefully assessed large sample of CHR 
adolescents (N = 62) in the same age range and from the same 
geographical area. The sample is double that of the intervention 
sample and allows for age and sex matching to individuals in 
the intervention study. Consequently, more resources can be 
allocated to recruiting the experimental group, and therefore, the 
chance of achieving a larger sample will be increased. This will 
also help to reduce ethical concerns, as the help-seeking patients 
will be reporting a high level of distress and requesting a specific 
treatment. The treatment is based on the current research results 
in the field of early intervention and prevention of psychosis, as 
well on the clinical expert knowledge from the therapists in the 
early intervention center. Therefore, our study team will act on 
the assumption that the treatment approach Robin will lead to 
the best possible outcome.
Another reason for utilizing a control group from a former 
study is the smartphone application Robin Z. Since the application 
can be downloaded for free from App Store and Google Play, 
it seems difficult to eliminate Robin Z as a confounder. Even if 
the therapists do not ask the control participants to download 
the application, their use of it cannot be ruled out. Although the 
usage of Robin Z alone will not replace treatment, the authors 
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assume that combination of psychological intervention and the 
use of the app will lead to a better psychological outcome.
To the authors’ knowledge, this is the first controlled trial to 
test the efficacy of a specific treatment manual in combination 
with a smartphone application for adolescent patients at 
CHR. The results of the study are expected to add important 
knowledge within the research fields of prevention and early 
intervention in psychosis in adolescents within the peak age of 
psychosis onset.
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